Biolife Solutions WKN: A1XCF2 ISIN: US09062W2044 Kürzel: BLFS Branche: Gesundheit, Medizinische, Instrumente, Zubehör
Marktkapitalisierung
695,7 Mio. EUR
KGV
-15,78
Ergebnis je Aktie
-1,02 EUR
k.A. % HL
Intervall: k.A.
High: k.A.
Low: k.A.
Börse: k.A.
k.A. % HL
Intervall: k.A.
High: k.A.
Low: k.A.
Börse: k.A.
k.A. % HL
Intervall: k.A.
High: k.A.
Low: k.A.
Börse: k.A.
k.A. % HL
Intervall: k.A.
High: k.A.
Low: k.A.
Börse: k.A.
k.A. % HL
Intervall: k.A.
High: k.A.
Low: k.A.
Börse: k.A.
k.A. % HL
Intervall: k.A.
High: k.A.
Low: k.A.
Börse: k.A.
k.A. % HL
Intervall: k.A.
High: k.A.
Low: k.A.
Börse: k.A.
k.A. % HL
Intervall: k.A.
High: k.A.
Low: k.A.
Börse: k.A.
Summer.76,
BIOLIFE SOLUTIONS
Hauptdiskussion, 21.11.2022 14:13 Uhr
https://www.prnewswire.com/news-releases/biolife-solutions-expands-intellectual-property-estate-301683442.html
Summer.76,
BIOLIFE SOLUTIONS
Hauptdiskussion, 10.05.2022 5:39 Uhr
BioLife Solutions Reports First Quarter 2022 Financial Results
https://www.prnewswire.com/news-releases/biolife-solutions-reports-first-quarter-2022-financial-results-301542982.html
Revenue of $36.2 million increased 115% over Q1 2021, with organic revenue growth of 45% and biopreservation media revenue growth of 53%
Affirms 2022 revenue guidance of $159.5 million to $171.0 million, reflecting year-over-year growth of 34% to 44% and organic growth of 28% to 39%
Sequential Improvement in Gross Margin and Adjusted EBITDA; on track for Continued Improvement in 2022, including positive adjusted EBITDA for the full year
Senior Management and Board to accept shares in lieu of a portion of cash compensation to signal confidence in the business
Summer.76,
BIOLIFE SOLUTIONS
Hauptdiskussion, 15.03.2022 16:20 Uhr
BioLife Solutions Secures Strategic Customer Wins and Plans 2022 Expansion in $400 Million Biostorage Services Market
https://www.prnewswire.com/news-releases/biolife-solutions-secures-strategic-customer-wins-and-plans-2022-expansion-in-400-million-biostorage-services-market-301502570.html
Summer.76,
BIOLIFE SOLUTIONS
Hauptdiskussion, 02.03.2022 21:54 Uhr
Temporary Setbacks At BioLife
https://seekingalpha.com/article/4492314-temporary-setbacks-at-biolife
Summary
• One of its acquired companies, Sterling, could not cope with the rapidly rising demand and this generated substantial one-off costs, marring the figures.
• However, underlying growth is very healthy, better actually than we expected.
• While the shares are still not cheap, they are a lot cheaper than they were even recently.
• When the problems are ironed out we think the shares can recover, although keep in mind this is a treacherous market.
...
Summer.76,
BIOLIFE SOLUTIONS
Hauptdiskussion, 02.03.2022 21:48 Uhr
Form NT 10-K - filed by Biolife Solutions Inc
https://newsfilter.io/a/a9590c1ff554a9affb16836334cf8917
...
BioLife Solutions, Inc. (the “Company”) is unable to file its Annual Report on Form 10-K for the year ended December 31, 2021 (the “2021 Form 10-K”) within the prescribed time period without unreasonable effort or expense. The Company is in the process of completing the financial statements to be included therein. The Company’s management is also in the process of assessing the effectiveness of the Company’s internal control over financial reporting. Although the assessment is not yet complete, the Company expects to report material weaknesses in the Company’s internal control over financial reporting. The Company expects to file the 2021 Form 10-K as soon as possible, but no later than March 16, 2022, the fifteenth calendar day following the prescribed due date of the 2021 Form 10-K.
...
Summer.76,
BIOLIFE SOLUTIONS
Hauptdiskussion, 28.02.2022 22:13 Uhr
BioLife Solutions Reports Unaudited Fourth Quarter and Full Year 2021 Financial Results
https://www.prnewswire.com/news-releases/biolife-solutions-reports-unaudited-fourth-quarter-and-full-year-2021-financial-results-301491979.html
Record quarterly revenue of $37.3 million up 153% over Q4 2020, with organic revenue growth of 64% and biopreservation media revenue growth of 64%
Record full year revenue of $119.2 million up 148% over 2020, with organic revenue growth of 37% and biopreservation media revenue growth of 39%
Initial guidance for 2022 total revenue at $159.5 million to $171 million, reflecting overall growth of 34% to 44% over 2021 and organic growth of 28% to 39%
Summer.76,
BIOLIFE SOLUTIONS
Hauptdiskussion, 16.12.2021 15:40 Uhr
UNICEF Selects Ultra-Low Temperature (ULT) Freezers from BioLife Solutions to Extend Thermal Stability of COVID-19 Vaccines
https://www.prnewswire.com/news-releases/unicef-selects-ultra-low-temperature-ult-freezers-from-biolife-solutions-to-extend-thermal-stability-of-covid-19-vaccines-301446062.html
Stirling Ultracold Freezers to be Used in Africa, the Middle East and South America
Summer.76,
BIOLIFE SOLUTIONS
Hauptdiskussion, 11.11.2021 22:33 Uhr
BioLife Solutions (BLFS) Misses Q3 EPS by 11c
https://www.streetinsider.com/dr/news.php?id=19200736
BioLife Solutions (NASDAQ: BLFS) reported Q3 EPS of ($0.20), $0.11 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $33.8 million versus the consensus estimate of $31.61 million.
GUIDANCE:
BioLife Solutions sees FY2021 revenue of $115-119 million, versus the consensus of $114.4 million.
Summer.76,
BIOLIFE SOLUTIONS
Hauptdiskussion, 11.11.2021 22:09 Uhr
BioLife Solutions Announces Third Quarter 2021 Financial Results
https://www.prnewswire.com/news-releases/biolife-solutions-announces-third-quarter-2021-financial-results-301422609.html
Total revenue up 200% over Q3 2020; organic revenue up 37% over Q3 2020 driven by 49% growth in media revenue
Raises full-year 2021 revenue guidance to $115 to $119 million, reflecting strong demand for proprietary biopreservation media products
Conference call begins at 4:30 p.m. Eastern time today
Summer.76,
BIOLIFE SOLUTIONS
Hauptdiskussion, 26.10.2021 15:41 Uhr
https://www.theglobeandmail.com/investing/markets/stocks/BLFS/pressreleases/2753568/
Biolife Solutions Supports Biostorage Best Practices Through SciSafe's "Centers of Excellence" With New World-Class Facility in Amsterdam
Summer.76,
BIOLIFE SOLUTIONS
Hauptdiskussion, 04.10.2021 21:42 Uhr
BioLife Solutions Leverages Expanded Bioproduction Tools and Services Portfolio in Multipoint Engagement with Leading CAR T-Cell Developer
https://www.prnewswire.com/news-releases/biolife-solutions-leverages-expanded-bioproduction-tools-and-services-portfolio-in-multipoint-engagement-with-leading-car-t-cell-developer-301391410.html
CryoStor® Freezer Media, evo® Smart Shipper and SciSafe® Storage Services All Utilized to Support Potential Q4 US Regulatory Approval and 2022 Commercial Launch
Summer.76,
BIOLIFE SOLUTIONS
Hauptdiskussion, 25.08.2021 17:50 Uhr
BioLife Solutions Joins S&P SmallCap 600 Index
https://markets.businessinsider.com/news/stocks/biolife-solutions-joins-s-p-smallcap-600-index-1030758292
...today announced that its common stock will be added to the S&P SmallCap 600 Index effective prior to the opening of trading on Monday, August 30, 2021. ...
Summer.76,
BIOLIFE SOLUTIONS
Hauptdiskussion, 12.08.2021 22:29 Uhr
BioLife Solutions Announces Second Quarter 2021 Financial Results
https://www.prnewswire.com/news-releases/biolife-solutions-announces-second-quarter-2021-financial-results-301354677.html
Total revenue grew 215% over Q2 2020 and 85% over Q1 2021
Organic revenue up 49% over Q2 2020 driven by 45% media revenue growth
Full year revenue guidance raised to $108 to $117 million, reflecting expected contribution from Sexton Biotechnologies
...
Summer.76,
BIOLIFE SOLUTIONS
Hauptdiskussion, 09.08.2021 22:21 Uhr
BioLife Solutions to acquire Sexton Biotechnologies
https://www.scienceboard.net/index.aspx?sec=ser&sub=def&pag=dis&ItemID=3107
Summer.76,
BIOLIFE SOLUTIONS
Hauptdiskussion, 13.05.2021 22:35 Uhr
BioLife Solutions EPS beats by $0.01, beats on revenue
https://seekingalpha.com/news/3696228-biolife-solutions-eps-beats-0_01-beats-on-revenue
BioLife Solutions (NASDAQ:BLFS): Q1 Non-GAAP EPS of $0.01 beats by $0.01; GAAP EPS of -$0.03 beats by $0.01.
Revenue of $16.85M (+38.6% Y/Y) beats by $0.8M.
Full year revenue guidance raised to $106 to $115 million vs. $105.65M reflecting confidence in outlook
|
|
Themen zum Wert | ||
|---|---|---|---|
| 1 | BIOLIFE SOLUTIONS Hauptdiskussion |
News zu Biolife Solutions
06.12.2022 11:00 Uhr • Meldungen • EQS News
Anzeige
![Weltweit handeln ab 0 Euro - Zum Depot]()
Kursdetails
| Geld (bid) | 15,60 (469) |
|---|---|
| Brief (ask/offer) | 16,00 (469) |
| Spread | 2,50 |
| Geh. Stück | 0 |
| Eröffnung | 16,10 |
| Vortag | 16,10 |
| Tageshoch | 16,10 |
| Tagestief | 15,80 |
| 52W Hoch | 23,00 |
| 52W Tief | 8,35 |
Tagesvolumen
| in USD gehandelt | 733 Tsd. Stk |
|---|---|
| in EUR gehandelt | 0 Stk |
| Gesamt | 733 Tsd. Stk |
Partner-News
Anzeige6:30 Uhr • Partner • Societe Generale
6:30 Uhr • Partner • BNP Paribas
6:30 Uhr • Partner • BNP Paribas
5:20 Uhr • Partner • onemarkets Blog
5:20 Uhr • Partner • onemarkets Blog
Aktien-News
8:30 Uhr • Artikel • BörsenNEWS.de
8:30 Uhr • Meldungen • EQS News
8:30 Uhr • Meldungen • EQS News
8:27 Uhr • Artikel • dpa-AFX
8:25 Uhr • Artikel • dpa-AFX
Geld/Brief Kurse
Neu laden| Börse | Geld | Vol. | Brief | Vol. | Zeit | Vol. ges. | Kurs |
|---|---|---|---|---|---|---|---|
| NYS | 17,01 | 300 Stk | 17,32 | 400 Stk | 1714003200 02:00 | 17,17 USD | |
| L&S Exchange | 15,60 | 469 Stk | 16,00 | 469 Stk | 1714026727 08:32 | 15,80 EUR | |
| AMEX | 17,43 | 100 Stk | 1714003200 02:00 | 17,31 USD | |||
| UTP Consolidated | 17,14 | 400 Stk | 17,19 | 800 Stk | 1714003200 02:00 | 525 Tsd. Stk | 17,19 USD |
| Baader Bank | 15,60 | 16,00 | 1714025504 08:11 | 15,80 EUR | |||
| Frankfurt | 15,60 | 257 Stk | 16,00 | 249 Stk | 1714025148 08:05 | 15,60 EUR | |
| Tradegate | 15,60 | 258 Stk | 16,00 | 250 Stk | 1713990399 24. Apr | 16,10 EUR | |
| Lang & Schwarz | 15,60 | 469 Stk | 16,00 | 469 Stk | 1714026724 08:32 | 15,80 EUR | |
| TTMzero RT | 1714025460 08:11 | 15,80 EUR | |||||
| Berlin | 15,60 | 3.000 Stk | 16,20 | 2.750 Stk | 1714025454 08:10 | 16,00 EUR | |
| Düsseldorf | 15,50 | 330 Stk | 16,10 | 330 Stk | 1714025456 08:10 | 15,60 EUR | |
| Stuttgart | 15,60 | 2.000 Stk | 16,00 | 2.000 Stk | 1714025051 08:04 | 15,60 EUR | |
| Gettex | 15,60 | 63 Stk | 16,00 | 63 Stk | 1714024875 08:01 | 16,00 EUR | |
| Quotrix Düsseldorf | 15,60 | 330 Stk | 16,00 | 330 Stk | 1714025460 08:11 | 15,80 EUR | |
| Nasdaq | 17,14 | 400 Stk | 17,19 | 800 Stk | 1714003200 02:00 | 208 Tsd. Stk | 17,19 USD | ges. 733.119 Stk |
Realtime / Verzögert
Börsennotierung
| Marktkapitalisierung in EUR |
|---|
| 695,7 Mio. |
| Anzahl der Aktien |
| 43,2 Mio. |
Termine
| 08.05.2024 | Quartalsmitteilung |
|---|---|
| 06.08.2024 | Quartalsmitteilung |
| 07.11.2024 | Quartalsmitteilung |
| 02/25 | Quartalsmitteilung |
Grundlegende Daten zur Biolife Solutions Aktie
| Finanzdaten | 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e |
|---|---|---|---|---|---|---|---|
| KUV | 27,32 | 13,03 | 4,81 | 5,08 | - | - | - |
| Ergebnis je Aktie (bereinigt) | 0,08 | -0,20 | -3,27 | -1,48 | -1,02 | - | - |
| Cashflow | 6,5 Mio. | -4,8 Mio. | -8,5 Mio. | -12,5 Mio. | - | - | - |
| Eigenkapitalquote | 87,40 % | 87,00 % | - | 81,82 % | - | - | - |
| Verschuldungsgrad | 14,41 | 14,95 | - | 22,23 | - | - | - |
| EBIT | -3,3 Mio. | -30,4 Mio. | -39,9 Mio. | -64,5 Mio. | - | - | - |
| Fundamentaldaten | 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e |
| KCV | 199,45 | -310,58 | -91,00 | -58,04 | - | - | - |
| Kurs-Gewinn-Verhältnis (KGV) | 498,63 | -186,35 | -5,57 | -10,98 | -15,78 | - | - |
| Bilanzdaten | 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e |
| Umsatzerlöse | 48,1 Mio. | 119,2 Mio. | 161,8 Mio. | 143,3 Mio. | - | - | - |
| Ergebnis vor Steuern | -0,6 Mio. | -28,7 Mio. | -0,1 Mrd. | -66,3 Mio. | - | - | - |
| Steuern | -3,3 Mio. | -20,3 Mio. | -5,0 Mio. | 169 Tsd. | - | - | - |
Info Biolife Solutions Aktie
Biolife Solutions
BioLife Solutions, Inc. entwickelt, produziert und liefert Bioproduktionswerkzeuge und Dienstleistungen für die Zell- und Gentherapieindustrie in den Vereinigten Staaten, Kanada, Europa, dem Nahen Osten, Afrika und international. Die Produkte des Unternehmens werden in der Grundlagen- und angewandten Forschung sowie in der kommerziellen Herstellung von Therapien auf biologischer Basis eingesetzt. Es bietet firmeneigene Medienprodukte für die Biokonservierung an, darunter HypoThermosol FRS und CryoStor, die so formuliert sind, dass sie konservierungsbedingte, verzögert auftretende Zellschäden und den Zelltod abmildern, sowie die ThawSTAR-Linie, die automatisierte Auftauprodukte für Fläschchen und Kryobeutel umfasst, die die Hitze und den Zeitpunkt des Auftauprozesses von biologischem Material steuern. Das Unternehmen bietet außerdem evo-Versandcontainer an, bei denen es sich um Cloud-verbundene passive Lager- und Transportcontainer für temperaturempfindliche biologische und pharmazeutische Produkte handelt, sowie Flüssigstickstoff-Laborgefriergeräte, Kryogeräte und Zubehör und biologische und pharmazeutische Lagerungsdienste. Das Unternehmen vermarktet und verkauft seine Produkte sowohl direkt als auch über Drittvertriebspartner. BioLife Solutions, Inc. wurde 1987 gegründet und hat seinen Hauptsitz in Bothell, Washington.